KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Non Operating Income (2016 - 2025)

AbbVie (ABBV) has disclosed Non Operating Income for 14 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 706.67% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.8 billion through Dec 2025, down 78.8% year-over-year, with the annual reading at -$5.8 billion for FY2025, 78.8% down from the prior year.
  • Non Operating Income for Q4 2025 was -$1.2 billion at AbbVie, down from -$503.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $776.0 million in Q1 2022, with the low at -$2.7 billion in Q2 2021.
  • Average Non Operating Income over 5 years is -$932.9 million, with a median of -$1.2 billion recorded in 2024.
  • The sharpest move saw Non Operating Income skyrocketed 1671.43% in 2022, then tumbled 1320.0% in 2024.
  • Over 5 years, Non Operating Income stood at -$216.0 million in 2021, then plummeted by 835.65% to -$2.0 billion in 2022, then grew by 23.01% to -$1.6 billion in 2023, then surged by 90.36% to -$150.0 million in 2024, then crashed by 706.67% to -$1.2 billion in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$1.2 billion, -$503.0 million, and -$2.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.